ClinicalTrials.gg
CompletedNCT02293915Updated Oct 10, 2018

An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease

A Phase 3 interventional study of Sodium oligo-mannurarate 900mg and Placebo in Mild to Moderate Alzheimer Disease and Cognitive Impairment, sponsored by Shanghai Greenvalley Pharmaceutical Co., Ltd.. Completed at 16 sites in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-10-10.

Sponsored by Shanghai Greenvalley Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Apr 2014, registered Nov 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
818
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 309 studies in Cognitive Dysfunction with a site in China — 143 open to participants now, 155 under way, 8 of them phase 3. Cognitive Dysfunction · China.

Enrollment
11th of 190
818 · median 110
Started
2014
with 4 others
Phase 3
12 of 309
4 open now
Registered
19th of 309
by date

Among the 309 studies in Cognitive Dysfunction with a site in China, this one is the 11th largest by enrollment of the 190 interventional ones that give a count, is one of 5 that started in 2014, is one of 12 in phase 3, and was the 19th registered.

Cognitive Dysfunction

3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

143 of the 309 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 309 studies in Cognitive Dysfunction with a site in China, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine the efficacy and safety of Sodium Oligo-mannurarate (GV-971) in 36-week treatment of mild to moderate Alzheimer's disease.

03

Conditions studied

  • Mild to Moderate Alzheimer Disease
  • Cognitive Impairment
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 50-85 years (inclusive), no gender limitation;
  2. Female subjects should be women (menopause >24 weeks), surgically sterilized women or women of child bearing age who agree to take effective measures during the trial. Women of child bearing age and women less than 24 weeks from menopause must undergo urine pregnancy test in screening period and result must be negative;
  3. Subjects have received education in primary school and above and are able to complete protocol specified cognitive ability test and other tests;
  4. Impaired memory for at least 12 months, with a tendency of progressive aggravation;
  5. Meet diagnostic criteria of probable AD according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) (1984);
  6. Patients with mild to moderate disease, i.e. 11 ≤total score ≤26 (for subjects with primary school education, 11 ≤total MMSE score ≤22);
  7. Total Hachinski Ischemia Scale (HIS) score ≤4 ;
  8. Total Hamilton Depression Scale/17-item (HAMD) score ≤10;
  9. In screening, cranial MRI plain scan and oblique coronal hippocampus scan must be performed, lacunar infarction lesions with a diameter larger than 2 cm ≤2, without lacunar infarction lesion in vital sites, such as thalamus, hippocampus, entorhinal cortex, paraolfactory cortex, cortex and other subcortical gray matter nuclei; MRI shows highest possibility of Alzheimer's disease (medial temporal lobe atrophy visual rating scale MTA grade ≥2);
  10. Neurological examination shows no significant sign;
  11. Subjects should have stable, reliable caregivers, or at least have frequent contact with caregivers (at least 4 days every week, at least 2 h every day), and caregivers will help patients in participation in this study. Caregivers must accompany subjects to participate in study visits and have sufficient interaction and communication with subjects, so as to provide valuable information on NPI, ADCS-ADL, CIBIC-plus scales.
  12. Before implementation of any protocol related procedure or examination, subjects must sign the written form. If subjects can not sign due to limited cognition, legal guardians should sign on behalf of subjects and meanwhile, legal guardians should also sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Participate in another clinical trial within 30 days prior to initiation of this study;
  2. Pregnant or nursing women;
  3. Dementia due to other causes: vascular dementia, central nervous system infection (e.g. AIDS, syphilis), Creutzfeldt-Jakob disease, Huntington's chorea, Parkinson's disease, dementia with Lewy bodies, traumatic dementia, other physical and chemical factors (e.g. drug poisoning, alcoholism, carbon monoxide poisoning), significant physical illness (e.g. hepatic encephalopathy, pulmonary encephalopathy), intracranial occupying lesion (e.g. subdural hematoma, brain tumor), endocrine disorders (e.g. thyroid disease, parathyroid disease) and dementia caused by vitamin or other factors;
  4. Previous nervous system disorders (including stroke, optic neuromyelitis, Parkinson's disease, epilepsy);
  5. Abnormal laboratory values: liver function (, AST) > 1.5 times of , Cr > 1.5 times of upper limit of normal, white blood cell count, , below the lower limit of normal, blood glucose >1.5 times of upper limit of normal;
  6. In screening, systolic blood pressure ≥160 mmHg or \<90 mmHg, or diastolic blood pressure ≥100 mmHg or \<60 mmHg;
  7. Unstable or severe cardiac, pulmonary, hepatic, renal or hematopoietic disease (including unstable angina, uncontrolled asthma, active gastric bleeding and cancer), after 10 min rest, resting heart rate \<55 bpm;
  8. Visual or hearing disorder, preventing completion of neuropsychological test and scale evaluation;
  9. In screening, MRI examination shows significant focal lesions, more than 2 lacunar infarction lesions with a diameter >2 cm, lacunar infarction lesions in vital sites, such as thalamus, hippocampus, entorhinal cortex, paraolfactory cortex, cortex and other subcortical gray matter nuclei; Fazekas scale for white matter lesions at ≥ grade 3;
  10. Alcohol abuse or drug abuse;
  11. Patients with psychosis, including severe depression;
  12. Patients who are using drugs for Alzheimer's disease which can not be stopped;
  13. Use of heparin, Propylene Glycol Mannurate Sulfate or Alginric Sodium Diester within 3 weeks prior to screening;
  14. Inability to take trial drugs according to prescription, previous non-compliance with prescription or possibility of non-compliance with study treatment in the trial;
  15. Investigators consider subjects can not complete this study;
  16. Subjects in the phase II trial of the study drug;
  17. Subjects are investigators participating in this study or their direct relatives, staff of Quintiles (Shanghai) or Shanghai Greenvalley Pharmaceutical Co., Ltd. or their direct relatives.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
818 participants (actual)

Study arms

  • Experimental
    sodium oligo-mannurarate 900mg

    Drug: Sodium oligo-mannurarate 900mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks

    Also known as: GV-971

  • DrugPlacebo

    simulant of sodium oligo-mannurarate capsule

06

What researchers measure

Primary outcomes

  1. Improvement of Alzheimer's Disease Assessment Scale-cognitive subscale(ADAS-cog)/12 of sodium oligo-mannurarate capsule

    Time frame: 36 weeks

Secondary outcomes

  1. Improvement of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) of sodium oligo-mannurarate capsule

    Time frame: 36 weeks

  2. Improvement of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) of sodium oligo-mannurarate capsule

    Time frame: 36 weeks

  3. Improvement of Neuropsychiatric Inventory(NPI) of sodium oligo-mannurarate capsule

    Time frame: 36 weeks

  4. Glucose metabolism of bilateral temporoparietal cortex

    Obtained by Positron Emission Tomography in two sites.

    Time frame: 36 weeks

07

Study locations

16 sites
  • Beijing
    Beijing, Beijing 100005, China
  • Chongqing
    Chongqing, Chongqing 400010, China
  • Fujian
    Fuzhou, Fujian, China
  • Guangzhou
    Guangzhou, Guangdong, China
  • Wuhan
    Wuhan, Hubei 430077, China
  • Changsha
    Changsha, Hunan, China
  • Nanjing
    Nanjing, Jiangsu, China
  • Suzhou
    Suzhou, Jiangsu, China
  • Yangzhou
    Yangzhou, Jiangsu, China
  • Jinan
    Jinan, Shandong 250021, China
  • Shanghai
    Shanghai, Shanghai 200030, China
  • Xi'an
    Xi'an, Shanxi, China
  • Sichuan
    Chengdu, Sichuan 610041, China
  • Tianjin
    Tianjin, Tianjin 300052, China
  • Hangzhou
    Hangzhou, Zhejiang 310016, China
  • Wenzhou
    Wenzhou, Zhejiang, China
08

References and documents

Publications

  • Ferrari C, Sorbi S. The complexity of Alzheimer's disease: an evolving puzzle. Physiol Rev. 2021 Jul 1;101(3):1047-1081. doi: 10.1152/physrev.00015.2020. Epub 2021 Jan 21. PubMed 33475022 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Jun 2018, 50 months.

Of 49 phase 3 interventional studies under Cognitive Dysfunction, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 63. This study's 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2014
First posted
Nov 19, 2014
StartActual
Apr 1, 2014
Primary completionActual
Jun 29, 2018
CompletionActual
Sep 28, 2018
Last update
Oct 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02293915
Lead sponsor
Shanghai Greenvalley Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 19, 2014
Start date
Apr 1, 2014
Primary completion
Jun 29, 2018
Completion
Sep 28, 2018
Last update
Oct 10, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GV-971

Start the discussion